Literature DB >> 21029835

Feasibility and clinical utility of transesophageal echocardiography in the acute phase of cerebral ischemia.

Stefano De Castro1, Federica Papetti, Emanuele Di Angelantonio, Biljana Razmovska, Giovanni Truscelli, Ursula Tuderti, Emanuele Puca, Agata Correnti, Marco Fiorelli, Massimiliano Prencipe, Danilo Toni.   

Abstract

We evaluated the feasibility and clinical utility of transesophageal echocardiography (TEE) in the early management of ischemic stroke. TEE was performed in consecutive patients with acute cerebral ischemia within 48 hours of symptoms onset. The data were analyzed by age (<55 vs ≥55 years), and the baseline stroke etiology was classified (determined vs undetermined). TEE was feasible in 660 (61%) of 1,080 patients. Left atrial abnormalities and complicated aortic plaques prevailed in older patients (p <0.05), irrespective of the stroke etiology. A patent foramen ovale prevailed in younger patients (p <0.05) but even in older patients was present in 13% of the determined and 31% of the undetermined stroke subgroups. Overall, high-risk and potentially high-risk cardioembolic sources were detected in 47% of the patients, and stroke etiology was consequently reviewed: 40% of the baseline undetermined strokes were reclassified as cardioembolic, and 29% of lacunar, 42% of large artery, and 30% of other determined-cause strokes were reclassified as concurrent etiology. Subsequently, according to the current guidelines, 12% of patients were reassigned from antiplatelet to anticoagulant therapy and 17% of patients were treated with high-dose statins; overall, secondary prevention treatment was modified in 26% of patients. In conclusion, TEE was feasible in about 2/3 of the patients investigated within 48 hours of the index event, contributed to stroke classification in 1/3 of cases, and guided secondary prevention therapy in 1/4 of patients. Therefore, TEE is useful for defining patients' risk profile for stroke recurrence.
Copyright © 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 21029835     DOI: 10.1016/j.amjcard.2010.06.066

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  8 in total

Review 1.  The value of transesophageal echocardiography for embolic strokes of undetermined source.

Authors:  Aristeidis H Katsanos; Rohini Bhole; Alexandra Frogoudaki; Sotirios Giannopoulos; Nitin Goyal; Agathi-Rosa Vrettou; Ignatios Ikonomidis; Ioannis Paraskevaidis; Konstantinos Pappas; John Parissis; Athanassios P Kyritsis; Anne W Alexandrov; Nikos Triantafyllou; Marc D Malkoff; Konstantinos Voumvourakis; Andrei V Alexandrov; Georgios Tsivgoulis
Journal:  Neurology       Date:  2016-08-03       Impact factor: 9.910

Review 2.  Anticoagulant vs. antiplatelet therapy in patients with cryptogenic stroke and patent foramen ovale: an individual participant data meta-analysis.

Authors:  David M Kent; Issa J Dahabreh; Robin Ruthazer; Anthony J Furlan; Christian Weimar; Joaquín Serena; Bernhard Meier; Heinrich P Mattle; Emanuele Di Angelantonio; Maurizio Paciaroni; Herwig Schuchlenz; Shunichi Homma; Jennifer S Lutz; David E Thaler
Journal:  Eur Heart J       Date:  2015-07-03       Impact factor: 29.983

3.  An assessment of annual procedure volumes and therapy adoption of transcatheter closure of patent foramen ovale in four European countries.

Authors:  Jan B Pietzsch; Benjamin P Geisler; Matthew J Daniels; Rachele M Busca; Giuseppe Tarantini; Lars Søndergaard; Scott E Kasner
Journal:  Eur Stroke J       Date:  2020-09-24

4.  Prevalence of patent foramen ovale in cryptogenic transient ischaemic attack and non-disabling stroke at older ages: a population-based study, systematic review, and meta-analysis.

Authors:  Sara Mazzucco; Linxin Li; Lucy Binney; Peter M Rothwell
Journal:  Lancet Neurol       Date:  2018-06-07       Impact factor: 59.935

5.  Transesophageal echocardiography in cryptogenic stroke and patent foramen ovale: analysis of putative high-risk features from the risk of paradoxical embolism database.

Authors:  Benjamin S Wessler; David E Thaler; Robin Ruthazer; Christian Weimar; Marco R Di Tullio; Mitchell S V Elkind; Shunichi Homma; Jennifer S Lutz; Jean-Louis Mas; Heinrich P Mattle; Bernhard Meier; Krassen Nedeltchev; Federica Papetti; Emanuele Di Angelantonio; Mark Reisman; Joaquín Serena; David M Kent
Journal:  Circ Cardiovasc Imaging       Date:  2013-11-08       Impact factor: 7.792

6.  An index to identify stroke-related vs incidental patent foramen ovale in cryptogenic stroke.

Authors:  David M Kent; Robin Ruthazer; Christian Weimar; Jean-Louis Mas; Joaquín Serena; Shunichi Homma; Emanuele Di Angelantonio; Marco R Di Tullio; Jennifer S Lutz; Mitchell S V Elkind; John Griffith; Cheryl Jaigobin; Heinrich P Mattle; Patrik Michel; Marie-Louise Mono; Krassen Nedeltchev; Federica Papetti; David E Thaler
Journal:  Neurology       Date:  2013-07-17       Impact factor: 9.910

Review 7.  Epidemiology of Patent Foramen Ovale in General Population and in Stroke Patients: A Narrative Review.

Authors:  Ioanna Koutroulou; Georgios Tsivgoulis; Dimitrios Tsalikakis; Dimitris Karacostas; Nikolaos Grigoriadis; Theodoros Karapanayiotides
Journal:  Front Neurol       Date:  2020-04-28       Impact factor: 4.003

8.  The risk of paradoxical embolism (RoPE) study: initial description of the completed database.

Authors:  David E Thaler; Emanuele Di Angelantonio; Marco R Di Tullio; Jennifer S Donovan; John Griffith; Shunichi Homma; Cheryl Jaigobin; Jean-Louis Mas; Heinrich P Mattle; Patrik Michel; Marie-Luise Mono; Krassen Nedeltchev; Federica Papetti; Robin Ruthazer; Joaquín Serena; Christian Weimar; Mitchell S V Elkind; David M Kent
Journal:  Int J Stroke       Date:  2012-08-09       Impact factor: 5.266

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.